Varian Medical Systems (NYSE: VAR) today is introducing the Halcyon™ system, an entirely new device for cancer treatment. Engineered to revolutionize clinical workflow, Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). This new treatment system is designed to expand the availability of high quality cancer care globally and help save the lives of millions more cancer patients.
“The global cancer challenge is enormous,” said Kolleen Kennedy, president of Varian's Oncology Systems business. “It is expected that there will be 24.6 million cancer cases diagnosed annually by 2030, and there is an acute shortage of equipment and trained clinicians. With the innovations in this new technology platform, the system will deliver high quality Halcyon treatments that empower clinicians to care for many more patients. At Varian we are very excited with the introduction of Halcyon to be taking another big step toward advancing cost-effective cancer care worldwide.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8065951-varian-medical-systems-halcyon-cancer-treatment/
Jason’s Deli and The University of Texas MD Anderson Cancer Center proudly introduce the new Salmon Pacifica Salad as part of an ongoing alliance to raise money to help end cancer for patients and families around the world.
Now through April 2018, 50 cents from the sale of every Salmon Pacifica Salad at participating Jason’s Deli restaurants will be donated to MD Anderson to support cancer prevention research and programs.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102251-jasons-deli-md-anderson-cancer-center-salmon-pacifica-salad/
Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
To view the multimedia release go to:
https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
The complete solution to managing vaginal dryness and discomfort inside and out is now available to the millions of women changing physically, emotionally and hormonally every day. The maker of #1 doctor recommended Replens™ vaginal moisturizer introduces hormone-free and fragrance-free Replens™ Moisture Restore External Comfort Gel, for soothing relief from external vaginal dryness, in menopause, post-partum, and after a cancer diagnosis.
“Ladies, don’t despair. Vaginal dryness can be a nuisance at any age. It’s one of the most common symptoms of menopause and unfortunately, can worsen over time. Luckily, there are non-hormonal products like Replens,” says Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University. “I recommend these products to patients as first line therapies to help relieve internal and external vaginal dryness.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8066251-replens-vaginal-moisture-restore-external-comfort-gel/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
In honor of World Pancreatic Cancer Day on Nov. 16, people around the world will come together to Demand Better in the fight against the world’s toughest cancer, starting with earlier diagnosis. The annual one-day campaign is an initiative of the World Pancreatic Cancer Coalition, which is comprised of more than 60 organizations from 27 countries on six continents.
Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer. Of that, an estimated 985 will die from the disease. Additionally, pancreatic cancer has the lowest survival rate among all major cancers, and in nearly every country, it is the only major cancer with a single-digit five-year survival rate (2-9 percent). These stunning figures are not merely statistics, they represent family members, friends and colleagues on every corner of the globe.
“This year, we are turning World Pancreatic Cancer Day from a day of awareness to a day of action,” said Julie Fleshman, JD, MBA, World Pancreatic Cancer Coalition chair. “As we expand our global movement to end pancreatic cancer, we are demanding better for pancreatic cancer patients now and in the future.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8201651-world-pancreatic-cancer-day-demand-better/
The Cancer Effect is the inspiring true story of one woman’s journey with cancer, written to provide hope and healing for patients, survivors, and those who love them. Moving, enlightening, uplifting, and honest. Learn more about this powerful memoir at www.claudiabretzing.com Non-fiction/self help
Let’s Win, an initiative supported by the Lustgarten Foundation, launched the Let’s Win! Pancreatic Cancer Survivors video series Friday, January 19, 2018, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The new online video series, featuring long-term pancreatic cancer survivors of all ages and diverse backgrounds, has been created to show pancreatic cancer patients and their families that people do survive this disease. The survivors have responded exceptionally well to pancreatic cancer therapy that incorporates clinical trials and treatments that go beyond traditional protocols.
When patients are first diagnosed with pancreatic cancer, they often turn to the internet, only to find devastating and frightening statistics about the disease. “Our goal is to provide hope and inspiration to patients and their families,” says Cindy Gavin, founding executive director of Let’s Win. “We are so grateful for the incredible vision of one special patient and the generosity of The Flora Family Foundation for their support of this incredible initiative.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213752-lets-win-pancreatic-cancer-survivor-video-series/
TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to help increase awareness of the growing need for clinical trial participants. The campaign, called “One Person Closer,” focuses on inspiring healthcare professionals (HCPs) to consider clinical research as a possibility for their patients, incorporate the topic into their daily practices, and have meaningful conversations with patients about opportunities to participate in clinical trials.
One Person Closer is designed to put a human face on research and development by sharing the personal stories of researchers, HCPs and patients who have contributed to clinical research and the development of medical breakthroughs. The photojournalist campaign aims to show doctors, nurses and other HCPs that they can help facilitate research that advances science and that may benefit their patients.
To view the multimedia release go to:
https://www.multivu.com/players/English/8268751-transcelerate-biopharma-one-person-closer/
